文献速递前列腺癌

调和前列腺穿刺组织学与磁共振成像可疑性之间的不一致:影像复审与反向融合靶区分析质量改进方案的实施

Reconciling Discordance Between Prostate Biopsy Histology and Magnetic Resonance Imaging Suspicion - Implementation of a Quality Improvement Protocol of Imaging Re-review and Reverse-fusion Target Analysis.
PubMed 文献 · Eur Urol Oncol · 2022-07-22

本文描述本机构在前列腺靶向穿刺未检出临床显著前列腺癌(csPCa)的不一致病例发生后启动的质量改进方案,该多学科复审流程包括mpMRI复审和评估病灶取样准确性的「反向融合」,文中介绍方案、展示示例病例并讨论临床意义。

要点

  • 靶向穿刺未检出csPCa时存在多种误差来源,包括mpMRI判读、融合、穿刺技术和组织学分类。
  • 本机构在出现不一致病例后启动多学科质量改进复审流程。
  • 该流程纳入mpMRI复审和评估病灶取样准确性的「反向融合」。

核心结论

  • 本文描述了本机构针对靶向穿刺与mpMRI可疑病灶不一致病例实施的质量改进方案,并讨论其临床意义。

研究设计与样本

  • 本机构实施的质量改进项目,在出现不一致病例后触发多学科复审流程。

主要发现

  • 不一致的可能误差来源包括mpMRI判读、mpMRI-超声融合、穿刺技术和组织学分类。
  • 本机构的质量改进流程包括mpMRI复审和评估病灶取样准确性的「反向融合」。

临床怎么用

  • 本研究中心的做法是,在不一致病例发生后启动多学科复审流程,纳入mpMRI复审和反向融合靶区分析。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is uncertainty with how to proceed when targeted prostate biopsy of suspicious multiparametric magnetic resonance imaging (mpMRI) lesions return without clinically significant prostate cancer (csPCa). While possible, there are error sources that could contribute to such discordance including the mpMRI read, mpMRI-ultrasound fusion, biopsy technique, and histologic classification. Consequences are potentially significant; mistakenly missing csPCa can lead to delays in curative treatment. Conversely, in cases of incorrect mpMRI interpretation, the patient may be subjected to unnecessary workup/burden. At our institution, we implemented a quality improvement (QI) initiative triggered after a discordant case occurs. This multidisciplinary review process incorporates mpMRI re-review and assessment of accurate lesion-sampling, termed "reverse-fusion." Herein, we describe the protocol, present sample cases, and discuss clinical implications.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Kotamarti S, Gupta RT, Wang B, et al. Reconciling Discordance Between Prostate Biopsy Histology and Magnetic Resonance Imaging Suspicion - Implementation of a Quality Improvement Protocol of Imaging Re-review and Reverse-fusion Target Analysis. Eur Urol Oncol. 2022. PMID: 35879190. doi:10.1016/j.euo.2022.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。